- Home
- STRT vs IVA Comparison
STRT vs IVA Comparison
Compare STRT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRT
- IVA
- Stock Information
- Founded
- STRT 1908
- IVA 2011
- Country
- STRT United States
- IVA France
- Employees
- STRT N/A
- IVA N/A
- Industry
- STRT Auto Parts:O.E.M.
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- STRT Consumer Discretionary
- IVA Health Care
- Exchange
- STRT Nasdaq
- IVA Nasdaq
- Market Cap
- STRT N/A
- IVA 359.6M
- IPO Year
- STRT 1995
- IVA 2020
- Fundamental
- Price
- STRT $36.60
- IVA $3.52
- Analyst Decision
- STRT
- IVA Strong Buy
- Analyst Count
- STRT 0
- IVA 4
- Target Price
- STRT N/A
- IVA $10.50
- AVG Volume (30 Days)
- STRT 19.2K
- IVA 20.0K
- Earning Date
- STRT 05-08-2025
- IVA 03-26-2025
- Dividend Yield
- STRT N/A
- IVA N/A
- EPS Growth
- STRT 6726.37
- IVA N/A
- EPS
- STRT 4.00
- IVA N/A
- Revenue
- STRT $552,799,000.00
- IVA $14,591,573.00
- Revenue This Year
- STRT $4.66
- IVA $15.38
- Revenue Next Year
- STRT $3.38
- IVA $24.22
- P/E Ratio
- STRT $9.16
- IVA N/A
- Revenue Growth
- STRT 7.69
- IVA N/A
- 52 Week Low
- STRT $21.05
- IVA $1.53
- 52 Week High
- STRT $53.01
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- STRT 50.90
- IVA 53.06
- Support Level
- STRT $33.26
- IVA $3.29
- Resistance Level
- STRT $35.89
- IVA $3.81
- Average True Range (ATR)
- STRT 2.15
- IVA 0.27
- MACD
- STRT 0.39
- IVA -0.04
- Stochastic Oscillator
- STRT 88.25
- IVA 32.91
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.